Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Hansen DK, Dima D, Mian H, Devos J, Brazauskas R, Oloyede T, Afrough A, Ahmed N, Anderson LD Jr, Banerjee R, Berdeja JG, Bidikian A, Dhakal B, Dias A, Efebera Y, Faisal MS, Gowda L, Hashmi H, Mirza AS, Mohan M, Narra R, Rosko AE, Schroeder M, Nishihori T, Landau H, Usmani S, Pasquini MC, Akhtar OS, Sidana S, Patel KK

Open source

DOI: 10.1038/s41408-026-01605-9
Published: 2026 Aug 31
Container: Blood cancer journal
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-026-01605-9,
  title = {Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.},
  author = {Hansen DK and Dima D and Mian H and Devos J and Brazauskas R and Oloyede T and Afrough A and Ahmed N and Anderson LD Jr and Banerjee R and Berdeja JG and Bidikian A and Dhakal B and Dias A and Efebera Y and Faisal MS and Gowda L and Hashmi H and Mirza AS and Mohan M and Narra R and Rosko AE and Schroeder M and Nishihori T and Landau H and Usmani S and Pasquini MC and Akhtar OS and Sidana S and Patel KK},
  year = {2026},
  journal = {Blood cancer journal},
  doi = {10.1038/s41408-026-01605-9},
  url = {https://doi.org/10.1038/s41408-026-01605-9}
}

RIS

TY  - JOUR
TI  - Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.
AU  - Hansen DK
AU  - Dima D
AU  - Mian H
AU  - Devos J
AU  - Brazauskas R
AU  - Oloyede T
AU  - Afrough A
AU  - Ahmed N
AU  - Anderson LD Jr
AU  - Banerjee R
AU  - Berdeja JG
AU  - Bidikian A
AU  - Dhakal B
AU  - Dias A
AU  - Efebera Y
AU  - Faisal MS
AU  - Gowda L
AU  - Hashmi H
AU  - Mirza AS
AU  - Mohan M
AU  - Narra R
AU  - Rosko AE
AU  - Schroeder M
AU  - Nishihori T
AU  - Landau H
AU  - Usmani S
AU  - Pasquini MC
AU  - Akhtar OS
AU  - Sidana S
AU  - Patel KK
PY  - 2026
JO  - Blood cancer journal
DO  - 10.1038/s41408-026-01605-9
UR  - https://doi.org/10.1038/s41408-026-01605-9
ER  -

APA

DK, H., D, D., H, M., J, D., R, B., T, O., A, A., N, A., Jr, A. L., R, B., JG, B., A, B., B, D., A, D., Y, E., MS, F., L, G., H, H., AS, M., M, M., R, N., AE, R., M, S., T, N., H, L., S, U., MC, P., OS, A., S, S., & KK, P. (2026). Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.. Blood cancer journal. https://doi.org/10.1038/s41408-026-01605-9

Source records

pubmed · retrieved 2026-09-26T13:55:03.271Z
doaj · retrieved 2026-09-26T13:55:03.279Z